Journal of Clinical Lipidology

Article	Citations
Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia	175
Hypercoagulability or coronary artery disease? Polygenic risk score unveils the mystery	135
Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practice	74
Assessment of health disparities in secondary ASCVD risk prevention in the elderly population in Greece	74
Effective treatment of statin- and ezetimibe-resistant hyperlipidemia in a patient with active membranous nephrotic syndrome using a PCSK9 inhibitor	74
Lipoprotein(a) concentrations across a global cross-sectional registry	67
Genetic mutations and associated phenotypes in familial hypercholesterolemia: A biobank study	60
Disparities in statin use among individuals with and without cancer history across atherosclerotic cardiovascular disease risk categories	60
Care of youth with lipid disorders: A brief provider survey	58
†Role of DNA methylation on 15-Lipoxygenase-1 gene expression in Osteoarthritis	56
Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis	51
Mesenchymal Stromal Cell (MSC) Therapy Improve Nonalcoholic Fatty Liver Disease (NAFLD) in Long Term high Fat Diet (HFD) Induced Obesity (DIO) Mouse	49
The Effect of Estrogen and Testosterone on Cholesterol Crystallization	47
Socioeconomic Disparities in Dyslipidemia and Associated Complications: From the Latest National Database	45
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes	45
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics - Implications for Precision Medicine	40
News from NLA	37
From the Editors: New insights into lipid disorders in children and adolescents as well as cardiovascular benefits of pharmacotherapy for weight loss	34
Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease	33
Evidence of Direct Hepatic Secretion of Low density Lipoprotein (LDL) in Mice	31
Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study	29
INFLAMMATION AND CARDIOMETABOLIC DISEASE IN SOUTH ASIANS: THE FIRE AND FIRE TENDERS	29
Niacin (Niacin) and clinical utility, don't be misled by recent niacin (Niacin) metabolite report	29
Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease	29
Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection	28

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association	27
Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: A systematic review and meta-analysis	27
Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the Americ	27
Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia	26
*Real-World Experience with Inclisiran at a Large Academic Lipid Clinic	25
Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia – Analysis of Secondary and Safety Endpoints from the APH-19 Study	25
From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated	25
News from the NLA	24
Possible explanations for the common clinical familial hypercholesterolemia phenotypes in the Faroe Islands	24
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study	24
A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia	23
Elevated lipoprotein(a) levels attenuate LDL-C lowering in acute coronary syndrome patients treated with triple combination lipid-lowering therapy	22
Cardiovascular and pregnancy outcomes in women with hyperlipidemia with and without hypertension: A real-world evidence study	21
Increased risk of ASCVD in women with PCOS is only partially mediated by incident metabolic comorbidities	20
Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)	20
Dyslipidemia among elderly patients with hyperuricemia and gout: Insights from the National Inpatient Sample	20
Acute pancreatitis events among patients with severe hypertriglyceridemia: A retrospective study	20
Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndrome	19
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk	18
Unique Case of Management of Severe Hypertriglyceridemia Secondary to Familial Chylomicronemia Syndrome	18
Table of Contents	17
Characterization of Inclisiran Use in Real World: Prescription Data from Germany	17
Remnant cholesterol and kidney disease progression in type 2 diabetes: A retrospective cohort study	16
The Healthy Eating Assessment Tool (HEAT): A Aimplified 10-Point Assessment of CHILD-2 Dietary Compliance for Children with Dyslipidemia	16
DISRUPTION OF HDL ANTIOXIDANT PROPERTIES IN CHILDREN AND ADOLESCENTS WITH OBESITY	16
⁎ Incidental Coronary Calcium on Non-Gated CT Scans of the Chest: A Stepwise Approach to Addressing Underreporting and Implementing Deep Learning	16
Health outcomes and survival among patients with severe hypertriglyceridemia after acute pancreatitis	16
Improvement of severe hypertriglyceridaemia in atypical subtype 4 partial lipodystrophy with volanesorsen	15
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study	15
Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study	14
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases	13
Disparities Among Gender and Racial Groups in the Achievement of Optimal Lipid Levels in Patients Following Acute Coronary Syndrome	13
Management of Atherogenic Dyslipidemia in a Patient with LDL Discordance	13
†Safety and Efficacy of Bempedoic Acid in Patients with Hypertension	13
Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis	13
*An Unsolved Case: FH or Sitosterolemia?	13
Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency	13
Editorial Board	13
Screening for Familial Hypercholesterolemia using Epic Secure Chat in Comparison to Epic Letter as Educational Outreach˄	13
Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease	13
Marked Hypoleptinemia precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy	13
Association of cumulative low-density lipoprotein cholesterol exposure with vascular function	12
The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study	12
Comparative cardiovascular outcomes of triple lipid-lowering therapy versus double therapy in patients with atherosclerotic cardiovascular disease	12
Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size	12
A Machine-Learning Algorithm using Claims Data to Identify Patients with Homozygous Familial Hypercholesterolemia (HoFH)	12
Evaluating the underutilization of lipid-lowering therapy in Asian patients – A high-risk population	12
Characteristics Associated with Inclisiran Initiation in Outpatient Physician Clinics	12
From the editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII	12
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins	12

Impact of baseline demographics on lipid profile in patients with ACS: Unmasking hidden drivers	12
Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?	11
Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients	11
The Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Program and Collaborative Learning Network (CL	11
Implementation strategies to optimize the use of nonstatin add-on lipid-lowering therapies in individuals with dyslipidemia: A systematic review	11
Corrigendum to “Association between the cardiometabolic index and mortality risk in US adults: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018” [Journal of Clinical L	11
Genetic Testing Results in a Preventative Cardiology and Inherited Lipid Disorders Clinic	11
Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome	11
Overcoming the real and imagined barriers to cholesterol screening in pediatrics	11
Genetic association analyses highlight apolipoprotein B as a determinant of chronic kidney disease in patients with type 2 diabetes	11
†Cardiovascular Trials Over the Last 15 years: Analysis of the Characteristics and Trends of ClinicalTrials.gov Listings from 2008 to 2022	11
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.	10
Novel APOB variant causes familial hypercholesterolemia in multiple unrelated families	10
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice	10
Long-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome: Data from an expanded access program	10
Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome	10
Multidisciplinary Management of Lipoprotein X-Induced Hyperlipidemia Secondary to Drug-Induced Liver Injury	10
Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia	10
Enzyme replacement therapy in cholesteryl ester storage disease: A case report on lysosomal acid lipase deficiency management	10
†Utility of AI-QCPA: Results of the Decisions for Treating Coronary Disease are Changed in Patients Evaluated with Quantified Plaque Analysis	10
^Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia	9
Concordance between LDL-C estimated by various formulas and directly measured LDL-C	9
Hourly 4-minute walking breaks from sitting following aerobic exercise reduce postprandial non-HDL cholesterol in healthy young adults: A randomized crossover trial	9
Community pharmacist impact of addressing statin use in patients with diabetes	9
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease	9
Functional profiling of LDLR variants: Important evidence for variant classification	9
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia	9
Enhancing lipoprotein(a) association studies: A complementary approach to principal component analysis	9
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia	9
ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk	8
Is Tangier disease a rare cause of premature ovarian insufficiency?: A case report	8
Why Are Patients Presenting with STEMI Already on Statin Not Treated with Additional Aggressive Lipid-lowering Agents?	8
An Indian adapted Mediterranean diet: A feasibility study	8
Sex differences in the associations of HDL particle concentration and cholesterol efflux capacity with incident coronary artery disease in type 1 diabetes: The RETRO HDLc cohort study	8
GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis	8
Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction	8
Habitual fish oil supplementation, genetic susceptibility of kidney stones and the risk of new-onset kidney stones	8
Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia	7
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Pre	7
Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option.	7
Table of Contents	7
From the editor: Heroes in a historic time	7
CAC Scoring as an Index for Subclinical Carotid Atherosclerosis	7
Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD	7
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America	7
Lipoprotein(a) screening for cardiac allograft vasculopathy among heart transplant recipients	7
Evaluation of plasma phytosterols in sitosterolemia, their kindreds and hyperlipidemia subjects	7
A novel homozygous nonsense variant of LMF1 in pregnancy-induced hypertriglyceridemia with acute pancreatitis	7
Spotlight on Abetalipoproteinemia and Related Hypobetalipoproteinemia Disorders: A Simplified Nomenclature and Clinical Guidelines. †	7
Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction	7
Fellow Quality Improvement Project: Identification of High Risk CAD Patients and Referral to Newly Established Lipid Clinic, What are the Clinical Implications?	7
Effects of evinacumab on high-density lipoprotein function in patients with homozygous familial hypercholesterolemia	7
Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography	7
Treatment dilemmas faced by women of reproductive age with familial hypercholesterolemia: Case report	7
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review	7
Dysbetalipoproteinamia: Implications for Pre-Conception, Pregnancy and Beyond	7
Validation of physical examinations of tendon xanthomas and changes in the cutoff values of Achilles tendon thickness on radiography in the clinical criteria of heterozygous familial hypercholesterole	6
Associations of Lipid-Lowering Drugs with Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study	6
Hyperlipidemia and risk for preclampsia	6
In memoriam: A tribute to Dr Scott M. Grundy	6
†Food Compass Score is Inversely Related to Inflammatory Markers and Cardiovascular Disease Incidence: Results from the ATTICA Cohort Study (2002-2022)	6
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia	6
Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases—Insights from a preventive cardio-rheuma clinic	6
Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye	6
† Cholesterol treatment trends from 2014 - 2023 in 3 Million US individuals with ASCVD: a retrospective cohort analysis using the Family Heart DatabaseTM	6
Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data	6
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults	6
No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized control	6
Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia	6
Association between very high HDL-C levels and mortality: A systematic review and meta-analysis	6
Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agen	6
Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia	6
Association of inclisiran initiation on oral antilipemic therapy discontinuation rates	6
Cardiovascular disease and cholesterol lowering therapy in women and men with molecularly defined heterozygous familial hypercholesterolemia from Brazil	6
*Sitosterolemia due to a new combination of ABCG8 variants presenting as hemolytic anemia and thrombocytopenia: A case report	6
Comprehensive analysis of Chinese patients with non-LPL familial chylomicronemia syndrome: Genetic variants, dietary interventions, and clinical insights	5
† Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia	5
Dedicated training in obesity management: A pathway to better physician practice	5
Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipid	5
What's next for lipoprotein(a)? A National Lipid Association report from an Expert Panel Discussion	5

Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial	5
Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors	5
Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform – Focus on LDL subclasses	5
The Food Compass Score is Negatively Related to the Activity of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Healthy Adults.	5
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention	5
Neurodegeneration in familial chylomicronemia syndrome	5
Discontinuation of lipid-modifying agents and failure to achieve target LDL cholesterol levels across cardiovascular risk groups	5
Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States	5
Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial	5
From the editor: Lipidology resurgent as the pandemic wanes	5
Long-term monitoring of LPL gene replacement therapy: A lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatments	5
+Racial Inequities in Coronary Artery Calcium Screening and Follow-up	5
Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial	5
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results	5
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk	5
SEX DIFFERENCES IN INFLAMMATORY BIOMARKERS DURING LONG-TERM EVOLOCUMAB THERAPY	5
Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome	5
Equitable Access to Screening and Lipid-Lowering Therapies in a Large Academic Center after Educational Interventions	5
Lipoprotein(a): Mirroring Familial Hypercholesterolemia	5
Lipedema is not obesity—A call for clinical clarity	4
One size doesn't fit all: A dose-dependent twist in PCSK9 monoclonal antibody therapy	4
Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia	4
†Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates	4
Prevalence, patterns, and geographical distribution of cardiometabolic multimorbidity and its association with unhealthy behaviors among Chinese adults: Evidence from the China National Nutrition Heal	4
Effect of Dexamethasone on Modulating Lp(a) Levels in COVID-19 Pneumonia	4
Racial Variations in SGLT2 Inhibitor Prescriptions	4
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?	4
Premature coronary artery disease in the absence of traditional risk factors - a hidden dilemma	4
From the editor: A compendium of lipidology progress	4
The analysis of the breakpoint of large rearrangements of LDLR gene in a Taiwanese cohort of patients with familial hypercholesterolemia	4
Pharmacotherapy development and trends in lipidology: An expert discussion	4
Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence	4
Evaluation of Lp(a) for cardiovascular disease risk prediction in the veteran's health administration	4
Severe Medication Induced Dyslipidemia in an Adult with Breast Cancer	4
Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein(a) Testing: The Multi-Ethnic Study of Atherosclerosis	4
† Higher Cardiovascular Event Rates for High-Risk Americans Who Did Not Meet 2018 Multidisciplinary Guideline on the Management of Blood Cholesterol Thresholds	4
Treatment Target Achievement in Patients with Familial Hypercholesterolemia: A Real-World Descriptive Study	4
Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice	4
Moderate Alcohol Consumption and Lipoprotein Subfractions: A Systematic Review of Intervention and Observational Studies	4
Utilizing gamification to educate internal medicine residents on managing lipids in patients with inflammatory conditions	4
*A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy.	4
New directions in childhood obesity treatment – A path forward or wishful thinking?	4
Association of lipoprotein(a) with peripheral artery disease and outcomes: A propensity-matched retrospective analysis	4
Editorial Board	4
Association of lipid-lowering drugs with gut microbiota: A Mendelian randomization study	4
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table	4
In memoriam, Avedis Khachadurian 1926 - Sept 22,2022	4
Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci	4
†Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome	4
Oral semaglutide and reduction in major adverse cardiovascular events	4
^Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia	4
Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the University of Pennsylvania Health System	3
Statin therapy for primary prevention in women: What is the role for coronary artery calcium?	3
Association between remnant cholesterol and culprit vessel physiological features in patients with acute coronary syndrome: An optical coherence tomography study	3
Assessing omega-3 fatty acids–critically weighing options and relevance	3
Kawasaki disease and familial hypercholesterolemia: Their potential synergistical impact on coronary arterial vascular health and viewpoints	3
A Single-Dose, Randomized, Open-Label, Two-Period Crossover Bioequivalence Study in Healthy Adults Comparing Two Subcutaneous Formulations of Olezarsen: (Vial and Autoinjector) at Two Dose Levels	3
Healthcare costs among acute pancreatitis patients with severe hypertriglyceridemia	3
Timing of PCSK9i Initiation and Its Relationship with Clinical Outcomes in US Patients with Prior Cardiovascular Events: A Claims Database Analysis	3
Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study	3
Racial disparities in LDL-C control, ASCVD risk reclassification by statin use, coronary artery calcium scores, and the Pooled Cohort Equation	3
†Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the Ocean and Rose2 Studies	3
Performance of the FIND-FH machine learning algorithm for the identification of individuals with suspected familial hypercholesterolemia	3
Case Report - Lysosomal Acid Lipase Deficiency - A Rare Cardiometabolic Disease and a NAFLD Mimic	3
Corrigendum to Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association [Journal of Clinical Lipidology Volume 13, Issue	3
Acknowledgement of Referees	3
Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients	3
Effect of hormone replacement therapy on in-hospital outcomes of ischemic stroke in older women with dyslipidemia: A large-scale nationwide analysis	3
Improving adherence with lipid-lowering agents	3
A case of lipoprotein glomerulopathy due to the pathogenic APOE Las Vegas variant c.509C > A: p. (Ala170Asp)	3
Diagnosis and Management of Familial Dysbetalipoproteinemia in a Patient with Apo E2/E2 Genotype	3
Severe Hypertriglyceridemia as a Cause of Arterial Thrombosis with Peripheral Embolic Complications.	3
CME Activity Highlights the Improvement in Clinician's Knowledge and Competence about Treatment Choices for LDL-C Lowering Post-MI	3
Impact of conducting a genetic study on the management of familial hypercholesterolemia	3
Guideline based eligibility for primary prevention statin therapy – Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI)	3
Missense mutation Q384K in the APOB gene affecting the large lipid transfer module of apoB reduces the secretion of apoB-100 in the liver without reducing the secretion of apoB-48 in the intestine	3
Assessing LDL-C goal attainment in secondary prevention of atherosclerotic cardiovascular disease: Insights from the LAI-LCARE survey in India	3
Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center	3
Suboptimal response to monoclonal antibodies to subtilisin/kexin type 9: A step towards personalizing approach to lipid-modifying therapy	3
Successful pregnancy outcome in a woman with cholesteryl ester storage disease treated with enzyme replacement therapy	3
Improving cholesterol management in high-risk primary prevention patients: An evidence-based case series	3
Unveiling Compound Heterozygous Familial Hypercholesterolemia	3
Pegylated-Asparaginase Induced Severe Hypertriglyceridemia in an Adult with Acute B-cell Lymphoblastic Leukemia	3
Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial	3
Lipids management in patients with diabetes mellitus: Experience from a cohort study in Greece.	3
Association of Systemic Inflammation with Lipid Profiles and Management in Patients with Rheumatoid Arthritis	2
Long-term cumulative exposure and variability of remnant cholesterol and risk of incident hypertension: A prospective cohort study (2002-2018)	2
Lipoprotein(a) knowledge, awareness, and clinical practice among physicians in the Arabian Gulf region	2
Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?	2
Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model	2
From the Editors: New concepts in obesity and cardiovascular disease	2
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran	2
Forty year follow-up of three patients with complete absence of apolipoprotein B-containing lipoproteins	2
Rare genetic cerebrotendinous xanthomatosis (CTX) cases without cholestanol elevation but with prominent cholesterol-rich tendon xanthomas	2
Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association	2